SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. Our robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). We are building a pipeline of oncology programs by pursuing promising early-stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts. Our company has established the key capabilities required for research, preclinical and clinical development, commercial planning, and market access, with the goal to rapidly advance the programs in our portfolio through clinical development towards commercialization.SOTIO is developing the next generation of potent immunotherapies for patients with cancer. To achieve this goal, we intend to acquire therapeutic oncology assets that are at advanced preclinical or clinical stages to include in our portfolio. We are looking for differentiated drugs of varying modalities (small molecules, biologics, cell therapies, etc.) that have the potential to make a real difference in patients suffering from cancer. SOTIO has research laboratories located in Prague (Czech Republic) and in Cambridge, MA. Both facilities collaborate with leading research teams and hospitals in the US and Europe. SOTIO has also direct access to the GMP manufacturing capabilities in Prague.

Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer.Cytune conceives and develops immunotherapeutic agents for fighting cancer (priority) and infectious diseasesImmunostimulatory agents: CYP0150 (Best-in Class category – Lead program)New generation of mAbs (mAbs conjugated to cytokines (immunocytokines or ICKs) – R&D Platform)Cancer immunotherapy: reset, restore & activate the defeated antitumor immune system.http://www.cytune-pharma.com/

ALTUM Consulting provides services to innovating companies:1 - Part-time CFO2 - Financing innovation through the framework of French Research Credit Taxes (i.e. Crédit Impôt Recherche, CIR) and "JEI" status and French/European public financing (BPI France, ANR, ANRT,...).

ATLAB Pharma aims at developing radioimmunotherapy as a breakthrough in cancer treatment.Radioimmunotherapy is a tumor-specific delivery system using monoclonal antibodies conjugated to radioisotopes (radio-antibodies) to target radiation to cancer cells wherever they have disseminated in the body, thus expanding the well-proven efficacy of radiotherapy from localized tumors to metastatic cancers.ATLAB Pharma is at the forefront of developing safe and efficient radio-antibodies based on new generation therapeutic radioisotopes Lutetium-177 and Astatine-211.ATLAB Pharma lead drug candidate, ATL101, has been shown to have a favorable safety profile and anti-tumor activity in Phase I and Phase II clinical trials in patients with castrate-resistant prostate cancer.http://www.atlab-pharma.com/

Advise and invest at innovation & growth stages in companies attractive to strategic buyers:+ Strong competitive advantage resulting in potential leadership in their strategic relevant markets+ Backed by robust intangible assets, such as patents, exclusive licenses, clinical data, trademarks+ Large enough enterprise value at exit (> 25 M CHF) to enter the radar screen of strategic buyershttp://www.remora-partners.ch

CITD provides value-added assistance to help local entrepreneurs to expand their business internationally. In order to make CITD more visible on the internet, I have taken part in the setting up of a marketing strategy based on social media/network tools.

I was in charge of auditing Research & Development (R&D) spendings as well as evaluating Research Projects. Working with a broad range of high tech companies allowed to develop a strong background in innovation and operational strategy. By providing advice in fiscal optimization and R&D organisation, I was able to secure tax returns of my customers with an economy comprised between 30 to 50 % of their research and development spending.I have collaborated with high-tech companies acting in different fields of innovative activities:- Bracer Biotech (Engineering & Cell Culture devices)- AGRO BIO (STAGO group, Immunology & Proteomic)- NOVARTIS PHARMA (Pharmaceutical group)- CHIESI France (Pharmaceutical group)- VIRBAC (Animal Health dedicated Laboratory)- Laboratoire SVR/EMULSCIENCE (Cosmetology)- Européenne de Produits de Beauté (REVLON, Cosmetology) - Laboratoire LEA (Cosmetology)- MOLLERTECH/EUROSTYLE (Automotive parts supplier)- VIPS France (Electronic and Engineering)- AMPLITUDE TECHNOLOGIES (Solid-state lasers development)- STREAMEZZO (Rich Media Technologies)

I was in charge of finding biotech and medtech start-ups in order to provide entrepreneurial assistance during the milestones of their development.

I have managed several research projects during which I have been in charge of students and technicians. I have taken part in building collaborations with different laboratories to group together the complementary competences required for the success of the projects.I have managed several research projects in relation with different pathologies such as cystic fibrosis, malaria and inflammatory diseases (IBS, IBD, Crohn’s disease).- Development of research activities and research project management- Supervision of research staff - Financing research- Scientific writing : Publications in international scientific press - Building collaborations